Literature DB >> 1672036

Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus.

.   

Abstract

Although guidelines have been established for prophylaxis against Pneumocystis carinii pneumonia (PCP) for adults with human immunodeficiency virus (HIV) infection, they have not been available for children (1). Experts in pediatric HIV infection (convened by the Pediatric HIV Resource Center) independently reviewed recent data and provided recommendations to the U.S. Public Health Service for PCP prophylaxis for HIV-infected or -exposed children. This report summarizes these deliberations and details the consensus guidelines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672036

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  10 in total

1.  Prophylaxis of Pneumocystis carinii pneumonia in HIV-infected children one to five years old: a multicenter surveillance study in paediatric hospitals in Germany.

Authors:  N Rümmelein; U Wintergerst; B H Belohradsky
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

2.  Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome.

Authors:  Yiwa Suksawat; Achara Sathienkijkanchai; Jittima Veskitkul; Orathai Jirapongsananuruk; Nualanong Visitsunthorn; Pakit Vichyanond; Punchama Pacharn
Journal:  J Clin Immunol       Date:  2017-04-20       Impact factor: 8.317

3.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

4.  Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children.

Authors:  M Mirochnick; E Cooper; K McIntosh; J Xu; J Lindsey; D Jacobus; L Mofenson; J L Sullivan; W Dankner; L M Frenkel; S Nachman; D W Wara; D Johnson; V R Bonagura; M H Rathore; C K Cunningham; J McNamara
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 5.  The diagnosis and classification of childhood HIV infection and disease.

Authors:  S Sen
Journal:  Indian J Pediatr       Date:  1994 Sep-Oct       Impact factor: 1.967

6.  How to structure clinical practice guidelines for continuous quality improvement?

Authors:  E A Balas; J Puryear; J A Mitchell; B Barter
Journal:  J Med Syst       Date:  1994-10       Impact factor: 4.460

7.  Protecting the weakest link: a proposal for universal, unblinded pediatric HIV testing, counselling and treatment.

Authors:  C Crawford
Journal:  J Community Health       Date:  1995-04

8.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

9.  Molecular detection of pneumocystis jirovecii in patients with respiratory tract infections.

Authors:  Oyebode Armstrong Terry Alli; David Olusoga Ogbolu; Olufunmi Ademola; Musiliu Adewale Oyenike
Journal:  N Am J Med Sci       Date:  2012-10

Review 10.  Treatment and prophylaxis of Pneumocystis carinii pneumonia in AIDS patients.

Authors:  D Smith; B Gazzard
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.